Mirum Pharmaceuticals (MIRM) Stock Price Target 2026

The average analyst price target for Mirum Pharmaceuticals is $124.23, 33.3% above the current price. Of 16 analysts, 16 rate it Buy. Targets range from $38 to $202. The latest change came on Nov 5, 2026, when Leerink Partners lowered its price target on Mirum Pharmaceuticals from $154 to $140 and kept an Outperform rating.

The Average Analyst Price Target for Mirum Pharmaceuticals is $124.23.

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

4S.Buy

12Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$124.23Upside to Avg. PT+33.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Mirum Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 5, 2026	Leerink Partners	Mani Foroohar	PT Cut	Outperform	$154→$140
Nov 4, 2026	RBC Capital	Lisa Walter	Maintained	Outperform	$155
Nov 4, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$144→$167
Nov 4, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$200→$202
Nov 4, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$155→$160
Oct 21, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$140→$145
Oct 15, 2026	Stifel	James Condulis	PT Raise	Buy	$136→$156
Oct 13, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$135→$146
Oct 13, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$137→$152
Oct 12, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$160→$184
Oct 12, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$195→$200
Oct 8, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$135→$155
Sep 29, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$145→$160
Sep 29, 2026	Baird	Brian Skorney	PT Raise	Outperform	$123→$130
Sep 28, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$140→$195
Aug 27, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$137
Aug 6, 2026	TD Cowen	Joseph Thome	PT Cut	Buy	$145→$140
Aug 6, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$148→$135
Aug 6, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$146→$137
Aug 6, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$185→$140

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.

Benzinga Newsdesk

PRO
CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

RBC Capital analyst Lisa Walter reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160

Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.

Benzinga Newsdesk

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals (MIRM) Stock Price Target 2026

The Average Analyst Price Target for Mirum Pharmaceuticals is $124.23.

Latest Upgrades and Downgrades for Mirum Pharmaceuticals Stock

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

PRO
CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

PRO
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202

PRO
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

People Also Watch

People Also Watch

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals (MIRM) Stock Price Target 2026

The Average Analyst Price Target for Mirum Pharmaceuticals is $124.23.

Latest Upgrades and Downgrades for Mirum Pharmaceuticals Stock

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

PROCORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

PROCitizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167

PROHC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202

PROCantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160

PROTD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

PRO
CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

PRO
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202

PRO
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145